Leerink Partners analyst David Risinger has maintained their bullish stance on ANAB stock, giving a Buy rating on February 28.
David Risinger has given his Buy rating due to a combination of factors including AnaptysBio’s strong financial performance and promising pipeline developments. The company reported significantly higher-than-expected revenue for the fourth quarter of 2024, largely driven by commercial milestones from GSK’s Jemperli sales. This financial upside, along with a net loss that was better than anticipated, supports a positive outlook for the company.
Additionally, AnaptysBio’s robust cash position, with $420.8 million in cash and investments, provides a solid financial runway through the end of 2027. The company’s pipeline is progressing well, with key upcoming events such as clinical data releases for rosnilimab and ongoing trials for early-stage assets like ANB033 and ANB101. Furthermore, the potential for milestone payments from Jemperli sales and long-term royalty revenue into the 2030s enhances the company’s growth prospects, despite potential competitive pressures in the future.
In another report released on February 28, Guggenheim also maintained a Buy rating on the stock with a $52.00 price target.
ANAB’s price has also changed dramatically for the past six months – from $36.840 to $16.400, which is a -55.48% drop .